ClinicalTrials.gg
CompletedNCT02660034Updated Dec 6, 2021Results posted

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of Tislelizumab and Pamiparib in Solid Tumors, sponsored by BeiGene. Completed at 29 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-06.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
229
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advanced solid tumors.

02

Conditions studied

  • Solid Tumors

Keywords

  • Dose Escalation
  • Dose Expansion
  • BGB-A317
  • BGB-290
  • Tislelizumab
  • Pamiparib
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants voluntarily agreed to participate by giving written .
  2. Must have received standard of care in the primary treatment of their disease.
  3. Participants who had the below specified confirmed that had progressed to the advanced or stage:

    1. In Part A, the participants must have had an advanced malignancy, including but not limited to high-grade serous cancer of the ovary, fallopian tube, or peritoneum, triple negative breast cancer, small cell lung cancer (SCLC), primary peritoneal cancer, and any tumor likely to harbor DNA damage repair deficiencies susceptible to treatment with a PARP inhibitor or likely to be responsive to a blocker.
    2. In Part B, the participants recruited to 1 of the 8 expansion arms must have had advanced solid tumors of the following types:

    Arm 1: Participants with , platinum-sensitive high-grade epithelial, non-mucinous, ovarian cancer, fallopian tube, or primary peritoneal cancer (EOC) must have met the following criteria:

    i. Must have had at least 2 prior platinum-containing treatments in any treatment setting.

    ii. Must have had platinum-sensitive recurrent disease and must not have progressed (by [RECIST] v1.1 criteria) within 6 months of the completion of the last platinum-containing .

    • Note: Participants may have received additional non-platinum-based chemotherapy for recurrence after prior last platinum-containing regimen if the criteria for platinum sensitivity were met.

    iii. Arm 1a: Participants with relapsed, platinum-sensitive high-grade EOC with either known deleterious or suspected deleterious germline or somatic breast cancer susceptibility gene 1/2 (BRCA1/2) mutations or with homologous recombination deficiency (HRD).

    • If HRD or BRCA1/2 mutation status from was unknown or had not been previously evaluated, then the archival tissue must have undergone tissue screening using a validated diagnostic test to determine eligibility. If the diagnostic test result was BRCA1/2 or HRD positive, the participant was eligible for enrollment in Arm 1a.

    iv. Arm 1b: Participants with relapsed, platinum-sensitive high grade EOC who otherwise met the above criteria and were without known germline or somatic BRCA1/2 mutations and without HRD mutation.

    Arm 2: Participants with triple negative breast cancer must have met the following criteria:

    i. 0-1 prior platinum-containing treatment in any treatment setting.

    • Note: participants could have received additional therapy after the last platinum-containing line of treatment if the other eligibility criteria were met.

    ii. Participants who received at least 1 prior treatment but not more than 3 prior lines of treatment in the advanced or metastatic setting.

    iii. Known deleterious or suspected deleterious germline or somatic BRCA1/2 mutations or with documented HRD.

    • If HRD or BRCA1/2 mutation status from archival tissue was unknown or had not been previously evaluated, then the archival tissue must have undergone tissue screening using a validated diagnostic test to determine eligibility. If the diagnostic test result was HRD positive, then the participant was eligible for enrollment in Arm 2.
    • If archival tissue was not available and the participant submitted a fresh tumor biopsy, then the diagnostic test needed to demonstrate somatic BRCA1/2 mutation or HRD positivity.

    Arm 3: Participants with metastatic castration-resistant prostate cancer, including but not limited to mutations in homologous recombination (HR) pathways and/or defined by HRD algorithms, and must have met the following criteria:

    i. May be either chemotherapy-naïve, but must have received prior abiraterone acetate and/or enzalutamide treatment, or have previously had no more than 2 taxane-based chemotherapy lines of treatment, including docetaxel and carbazitaxel. If docetaxel was used more than once, this was considered as 1 line of treatment.

    ii. At least 2 weeks since the completion of prior flutamide, bicalutamide, and nilutimide, or enzalutamide and abiraterone treatment.

    iii. Documented prostate cancer with one of the following:

    • Surgically or medically castrated. The testosterone levels did not need to be checked if the participant had undergone surgical castration for > 4 months. Participants receiving chemical castration should have had testosterone levels checked at baseline and confirmed to be in the castrate levels (\< 0.5 ng/mL or 1.735 nM). In all cases, the luteinizing hormone-releasing hormone antagonist/agonist was to be continued in these participants.
    • Participants with only non-measurable bone lesions must have had disease progression based on Prostate Cancer Clinical Trials Working Group with 2 or more new lesions or have had prostate-specific antigen progression before enrolment.

    iv. Known deleterious or suspected deleterious germline or somatic BRCA1/2 mutations or with documented HRD.

    • If HRD or BRCA1/2 mutation status from archival tissue was unknown or had not been previously evaluated, then the archival tissue must have undergone tissue screening using a validated diagnostic test to determine eligibility. If the diagnostic test result was HRD positive, then the participant was be eligible for enrollment in Arm 3.
    • If archival tissue was not available and the participant summitted a fresh tumor biopsy, then the diagnostic test needed to demonstrate somatic BRCA1/2 mutation or HRD positivity.

    Arm 4: Participants with extensive-stage disease SCLC must have met the following criteria:

    i. Received at least 1 and not more than 2 prior lines of treatment; ii. At least 1 prior line of treatment must have contained a platinum agent

    Arm 5: Participants with human epidermal growth factor receptor-2 ()-negative gastric or gastroesophageal junction cancer must have met the following criteria:

    i. May have received at least 1 and not more than 2 prior lines of treatment

    Arm 6: Participants with locally advanced or metastatic urothelial (muscle-invasive bladder, ureter, urethra, or renal pelvis) cancer must have met the following criteria:

    i. Received at least 1 and not more than 2 prior lines of treatment in the advanced or metastatic disease setting; ii. At least 1 prior line of treatment must have contained a platinum agent

    Arm 7: Participants with advanced or metastatic pancreatic adenocarcinoma must have met the following criteria:

    i. Received at least 1 but not more than 2 lines of treatment in either an advanced or metastatic setting; ii. At least 1 prior treatment for advanced or metastatic disease must have contained a platinum agent; iii. Participants with known deleterious germline or somatic BRCA1/2 mutation could be considered for the study even if platinum naïve.

    Arm 8: (Note: Closed to enrollment) Participants with advanced or metastatic recurrent non-ovarian gynecological cancers (endometrial cancer, cancer of the cervix and participants with tumors known to be mismatch repair deficient or HRD positive) must have met the following criteria:

    i. Participants with a complete response, partial response, or stable disease from at least 1 prior platinum-containing treatment in any treatment setting; ii. The Sponsor medical monitor would approve tumor types for Arm 8 prior to screening.

    • Note: Excluded tumor types included participants with bone or soft tissue sarcoma; central nervous system (CNS) malignancies; colorectal cancer (except microsatellite instability-high colorectal cancer is permitted); cutaneous or ocular melanoma; hematologic malignancies; HER2-negative breast cancer without BRCA mutation; mesothelioma, papillary, follicular, medullary or Hürthle cell thyroid cancer; unknown primary malignancy.
  4. Participants who were treated with chemotherapy or any therapies, if eligible, must have completed at least 4 weeks or at least 5 half-lives (whichever is longer, but no less than 3 weeks) before the study drug administration, and all adverse events (AEs) had either returned to baseline or stabilized.
  5. At least 2 weeks from palliative radiotherapy.
  6. Participants must have had archival tumor tissue or agree to a tumor biopsy for mutation and biomarkers analysis unless previously discussed with Sponsor's medical monitor or its designee (fresh tumor biopsies were recommended at baseline in participants with readily accessible tumor lesions and who consented to the biopsies). Participants with ovarian, fallopian tube, primary peritoneal, or breast cancer in Part A and all participants enrolled in Part B must also have agreed to provide fresh blood sample at the baseline for the evaluation of BRCA mutations and/or confirmation of prior BRCA results or other HR deficiency mutations, even if it was previously tested.
  7. Participants must have had as defined in RECIST v1.1. Participants with metastatic castration-resistant prostate cancer and epithelial, non-mucinous, ovarian cancer, fallopian tube, or primary peritoneal cancer may have used separate disease-specific criteria.
  8. Male or female ≥ 18 years of age on the day of signing informed consent.
  9. Must have had an Performance Status ≤ 1.
  10. Must have had a ≥ 12 weeks.
  11. Must have had adequate organ function.
  12. Females of must have been willing to use a highly effective method of for the duration of the study, and for at least 6 months after the last dose of investigational drug, and have had a negative serum pregnancy test within 7 days of the first dose of study drug(s).
  13. Non-sterile males and their female partners must have been willing to use a highly effective method of birth control for the duration of the study and for at least 6 months after the last dose of investigational drug. Nonsterile males must have avoided sperm donation for the duration of the study and for at least 6 months after last study drug.
  14. Females must have agreed not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration.

Key Exclusion Criteria:

  1. Participants with ovarian cancer who have platinum-resistant/refractory disease, defined as progressive disease at the first tumor assessment while receiving platinum-containing chemotherapy.
  2. Participant had history of severe reactions to other mAbs.
  3. Any major surgery within 28 days before first dose of study drugs.
  4. Prior stem cell transplantation or organ transplantation.
  5. Participants with toxicities (as a result of prior anticancer therapy) that had not recovered to baseline or stabilized, except for AEs not considered a likely safety risk (for example, alopecia, neuropathy and specific laboratory abnormalities).
  6. Concurrent participation in another clinical trial.
  7. Prior malignancy within the previous 2 years except for locally curable non-melanoma dermatologic cancers that had been apparently cured, such as basal or squamous cell skin cancer, or carcinoma in situ of the skin, cervix, breast, bladder, or prostate.
  8. Symptomatic or . Note: Baseline magnetic resonance imaging of the brain and spinal cord was required for SCLC participants enrolled in Arm 4 if they had a history of CNS disease.

    Note: Participants with previously treated CNS metastatic disease were eligible for any arm if CNS metastatic disease was asymptomatic, clinically stable, and did not require or anticonvulsants within a minimum of 4 weeks of enrollment.

  9. Prior therapies targeting PD-1, programmed death-ligand 1 (PD-L1), or PARP.
  10. Active diseases or history of autoimmune diseases that may have relapsed.

    Note: Participants with the following diseases were not excluded and may have proceeded to further screening:

    1. Controlled Type I diabetes;
    2. Hypothyroidism managed with no treatment other than with hormone replacement therapy;
    3. Controlled celiac disease;
    4. Skin diseases not requiring systemic treatment (for example, vitiligo, psoriasis, alopecia);
    5. Any other disease that was not expected to recur in the absence of external triggering factors.
  11. Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other medication within 2 weeks of the study drug administration.

    Note: Participants who were currently or had previously been on any of the following steroid regimens were not excluded:

    1. Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent);
    2. Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with minimal systemic absorption;
    3. Short course (≤ 7 days) of corticosteroid prescribed prophylactically (for example, for contrast dye allergy) or for the treatment of a non-autoimmune condition (for example, delayed-type hypersensitivity reaction caused by contact allergen).
  12. With severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, et cetera.
  13. History of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung diseases, et cetera.
  14. History of non-viral hepatitis or cirrhosis.
  15. Positive status.
  16. A known history of virus or virus infection.
  17. History of alcohol abuse.
  18. Underlying medical conditions or alcohol or drug abuse or dependence that, in the investigator's opinion, would be unfavorable for the administration of study drug or affect the explanation of drug toxicity or AEs; or insufficient compliance during the study according to investigator's judgement.
  19. Inability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening, or otherwise altering the product formulation. Participants should not have had gastrointestinal illnesses that would have precluded the absorption of pamiparib, which was an oral agent.
  20. Had been administered a within 4 weeks (28 days) of initiation of study therapy.
  21. Any of the following cardiovascular criteria:

    1. Current evidence of cardiac ischemia;
    2. Current symptomatic pulmonary embolism;
    3. Acute myocardial infarction ≤ 6 months prior to Day 1;
    4. Heart failure of Classification III or IV ≤ 6 months prior to Day 1;
    5. Grade ≥ 2 ventricular arrhythmia ≤ 6 months prior to Day 1;
    6. History of cerebrovascular accident within 6 months before first dose of study drugs.
  22. Use or had anticipated need for food or drugs known to be strong or moderate cytochrome P450 (CYP)3A inhibitors or strong inducers ≤ 10 days (or ≤ 5 half-lives, whichever is shorter) prior to Day 1.

Note: Other protocol-defined Inclusion/Exclusion criteria may have applied.

Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
229 participants (actual)

Study arms

  • Experimental
    Part A: Dose Escalation Phase

    Participants received tislelizumab and pamiparib (dose escalation) until determination of the maximum tolerated dose/recommended Phase 2 dose.

    Biological: Tislelizumab · Drug: Pamiparib

  • Experimental
    Part B: Dose Expansion Phase

    Participants received tislelizumab and pamiparib (dose expansion).

    Biological: Tislelizumab · Drug: Pamiparib

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Number Of Participants Experiencing Adverse Events (AEs)

    An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. All AEs reported are treatment-emergent, which was defined as having a reported onset time or worsening in severity on or after the date of the first dose of study treatment through 30 days after the last dose (permanent discontinuation of study treatment) or initiation of new anticancer therapy. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: From Day 1 up to 4 years and 7 months

  2. Part A: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)

    DLT was defined as an AE or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications, and occurs during the first 21 days following the first dose of tislelizumab and pamiparib in Cycle 1 and meets protocol-specified criteria. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: 21 days following the first dose of tislelizumab and pamiparib in Cycle 1

  3. Part B: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a best overall response of complete response (CR) and partial response (PR).

    Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)

  4. Part B: Progression-free Survival (PFS)

    PFS was defined as the time from first dose of study medication to the first documented objective disease progression or death due to any cause, whichever occurred first.

    Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)

  5. Part B: Duration Of Response (DOR)

    DOR, defined as the time from the first determination of an objective response, was assessed by investigator per Response Evaluation Criteria in Solid Tumors v1.1 until the first documentation of progression or death, whichever occurred first. Results are reported only for arms with responders.

    Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)

  6. Part B: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with a best overall response of CR, PR, and stable disease (SD).

    Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)

  7. Part B: Clinical Benefit Rate (CBR)

    CBR was defined as the percentage of participants with a best overall response of CR, PR, and SD lasting ≥ 24 weeks.

    Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)

  8. Part B: Overall Survival (OS)

    OS was defined as the time from the date of first dose of study drug to death due to any cause.

    Time frame: From Day 1 Every 3 months following completion or discontinuation of the treatment (up to 4 years and 7 months)

Secondary outcomes

  1. Part A: Minimum Observed Plasma Concentration (Ctrough) Of Tislelizumab

    Time frame: Cycle 4 Day 1 (0 hours and 4 hours) post dose

  2. Part A: Ctrough Of Pamiparib

    Time frame: Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)

  3. Part A: Maximum Observed Plasma Concentration At Steady State (Cmax,ss) Of Pamiparib

    Time frame: Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)

  4. Part A: Time To Reach Maximum Plasma Concentration At Steady State (Tmax,ss) Of Pamiparib

    Time frame: Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)

  5. Part A: Ctrough At Steady State (Ctrough,ss) Of Pamiparib

    Time frame: Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)

  6. Part A: ORR

    ORR was defined as the percentage of participants with a best overall response of CR and PR.

    Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)

  7. Part A: PFS

    PFS was defined as the time from first dose of study medication to the first documented objective disease progression or death due to any cause, whichever occurred first.

    Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)

  8. Part A: DCR

    DCR was defined as the percentage of participants with a best overall response of CR, PR, and SD.

    Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)

  9. Part A: CBR

    CBR was defined as the percentage of participants with a best overall response of CR, PR, and SD lasting ≥ 24 weeks.

    Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)

  10. Part A: OS

    OS was defined as the time from the date of first dose of study drug to death due to any cause.

    Time frame: Starting from Day 1 Every 3 months following completion or discontinuation of the treatment (up to 4 years and 7 months)

  11. Part A: Percentage Of Participants With Anti-drug Antibodies (ADAs) For Tislelizumab

    Immunogenicity was summarized by participants who were ADA positive and developed detectable ADAs.

    Time frame: Within 24 hours before the start of the first dose of tislelizumab in Cycle 1, Day 8 of Cycle 1, and Day 1 of Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 9, and Cycle 17

  12. Part B: Number Of Participants Experiencing AEs

    An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. All AEs reported are treatment-emergent, which was defined as having a reported onset time or worsening in severity on or after the date of the first dose of study treatment through 30 days after the last dose (permanent discontinuation of study treatment) or initiation of new anticancer therapy. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Day 1 of Cycle 1 up to 4 years and 7 months

  13. Part B: Ctrough Of Tislelizumab

    As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.

    Time frame: Cycle 4 Day 1 ( 0 hours and 4 hours post dose)

  14. Part B: Maximum Observed Plasma Concentration (Cmax) Of Tislelizumab

    As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.

    Time frame: Cycle 4 Day 1 ( 0 hours and 4 hours) post dose

  15. Part B: Ctrough Of Pamiparib

    As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.

    Time frame: Cycle 2 Day 1 (7 hours Post-dose)

  16. Part B: Cmax Of Pamiparib

    As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.

    Time frame: Cycle 2 (7 hours Post-dose)

  17. Part B: Percentage Of Participants With ADAs For Tislelizumab

    Immunogenicity was summarized by participants who developed detectable ADAs. Treatment-emergent ADAs: sum of both treatment-induced ADAs and treatment-boosted ADAs.

    Time frame: 24 hours predose of Day 1 of every cycle

07

Results

Posted Dec 6, 2021

Participant flow

Part A: A total of 49 participants with advanced solid tumors were enrolled in Part A of the study (dose escalation phase) at a total of 5 sites or community oncology centers in Australia. Part B: A total of 180 participants with advanced solid tumors were enrolled in Part B of the study (dose expansion phase).

Participant flow — Overall Study
MilestonePart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5Part B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8
Started12126136232319202320212110
Received at least 1 dose of study drug(s)12126136232319202320212110
Completed00000000000000
Not completed12126136232319202320212110
Withdrew: Progressive disease (radiographic)31010000000000
Withdrew: Progressive disease (clinical)78393000000000
Withdrew: Lost to follow-up00110000011100
Withdrew: Participant moved into special access scheme12000000000000
Withdrew: Adverse event10000000000000
Withdrew: Sponsor decision01223000000001
Withdrew: Withdrawal by subject00000011100120
Withdrew: Death000001314109211715187
Withdrew: Physician decision00000000000001
Withdrew: Participants transferred to lte0000010881012411

Outcome measures

PrimaryPart A: Number Of Participants Experiencing Adverse Events (AEs)

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. All AEs reported are treatment-emergent, which was defined as having a reported onset time or worsening in severity on or after the date of the first dose of study treatment through 30 days after the last dose (permanent discontinuation of study treatment) or initiation of new anticancer therapy. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
From Day 1 up to 4 years and 7 months
Reported as:
Count of participants · Participants
Part A: Number Of Participants Experiencing Adverse Events (AEs)
ParticipantsPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Part A: Number Of Participants Experiencing Adverse Events (AEs)12126136
PrimaryPart A: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)

DLT was defined as an AE or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications, and occurs during the first 21 days following the first dose of tislelizumab and pamiparib in Cycle 1 and meets protocol-specified criteria. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
21 days following the first dose of tislelizumab and pamiparib in Cycle 1
Reported as:
Count of participants · Participants
Part A: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)
ParticipantsPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Part A: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)00022
PrimaryPart B: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with a best overall response of complete response (CR) and partial response (PR).

Time frame:
Starting from Day 1 until disease progression (up to 4 years and 7 months)
Reported as:
Count of participants · Participants
Part B: Objective Response Rate (ORR)
ParticipantsPart B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8
Part B: Objective Response Rate (ORR)739422603
PrimaryPart B: Progression-free Survival (PFS)

PFS was defined as the time from first dose of study medication to the first documented objective disease progression or death due to any cause, whichever occurred first.

Time frame:
Starting from Day 1 until disease progression (up to 4 years and 7 months)
Reported as:
Median · month
Part B: Progression-free Survival (PFS)
monthPart B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8
Part B: Progression-free Survival (PFS)8.2 (5.2 to 11.8)3.5 (1.9 to 7.6)8.4 (3.9 to 19.0)10.4 (4.3 to 16.2)2.0 (1.7 to 2.3)2.1 (1.9 to 4.1)3.5 (1.9 to 7.5)1.9 (1.1 to 2.1)2.2 (1.2 to 24.4)
PrimaryPart B: Duration Of Response (DOR)

DOR, defined as the time from the first determination of an objective response, was assessed by investigator per Response Evaluation Criteria in Solid Tumors v1.1 until the first documentation of progression or death, whichever occurred first. Results are reported only for arms with responders.

Time frame:
Starting from Day 1 until disease progression (up to 4 years and 7 months)
Reported as:
Median · months
Part B: Duration Of Response (DOR)
monthsPart B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 8
Part B: Duration Of Response (DOR)11.2 (6.2 to NA)6.2 (3.8 to NA)17.1 (3.0 to NA)NA (4.1 to NA)6.2 (4.3 to 8.1)NA (NA to NA)NA (5.7 to NA)NA (22.4 to NA)
PrimaryPart B: Disease Control Rate (DCR)

DCR was defined as the percentage of participants with a best overall response of CR, PR, and stable disease (SD).

Time frame:
Starting from Day 1 until disease progression (up to 4 years and 7 months)
Reported as:
Count of participants · Participants
Part B: Disease Control Rate (DCR)
ParticipantsPart B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8
Part B: Disease Control Rate (DCR)21111415771224
PrimaryPart B: Clinical Benefit Rate (CBR)

CBR was defined as the percentage of participants with a best overall response of CR, PR, and SD lasting ≥ 24 weeks.

Time frame:
Starting from Day 1 until disease progression (up to 4 years and 7 months)
Reported as:
Count of participants · Participants
Part B: Clinical Benefit Rate (CBR)
ParticipantsPart B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8
Part B: Clinical Benefit Rate (CBR)157111044813
PrimaryPart B: Overall Survival (OS)

OS was defined as the time from the date of first dose of study drug to death due to any cause.

Time frame:
From Day 1 Every 3 months following completion or discontinuation of the treatment (up to 4 years and 7 months)
Reported as:
Median · month
Part B: Overall Survival (OS)
monthPart B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8
Part B: Overall Survival (OS)20.9 (13.5 to NA)18.7 (6.1 to 27.0)15.8 (10.4 to NA)21.2 (10.5 to NA)6.9 (3.3 to 11.5)7.4 (3.3 to 13.4)8.4 (4.4 to 17.1)4.1 (2.9 to 5.0)4.1 (1.2 to 19.5)
SecondaryPart A: Minimum Observed Plasma Concentration (Ctrough) Of Tislelizumab
Time frame:
Cycle 4 Day 1 (0 hours and 4 hours) post dose
Reported as:
Geometric mean · nanogram/milliliter
Part A: Minimum Observed Plasma Concentration (Ctrough) Of Tislelizumab
nanogram/milliliterPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Cycle 4 Day 1 (Pre-dose)23530 ± 48.0226040 ± 58.0426160 ± 23.6930330 ± 58.2853700 ± 81.62
Cycle 4 Day 1 (4 h)74260 ± 20.7066250 ± 47.2869020 ± 16.47104300 ± 35.31119600 ± 33.83
SecondaryPart A: Ctrough Of Pamiparib
Time frame:
Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)
Reported as:
Geometric mean · nanogram/milliliter
Part A: Ctrough Of Pamiparib
nanogram/milliliterPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Cycle 2 Day 1 (Pre-dose)772.9 ± 164.61258 ± 62.131209 ± 42.181876 ± 60.412754 ± 48.69
Cycle 2 Day 1 (7 h)824.8 ± 130.61469 ± 38.141717 ± 55.562070 ± 47.362969 ± 48.77
SecondaryPart A: Maximum Observed Plasma Concentration At Steady State (Cmax,ss) Of Pamiparib
Time frame:
Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)
Reported as:
Number · nanogram/milliliter
Part A: Maximum Observed Plasma Concentration At Steady State (Cmax,ss) Of Pamiparib
nanogram/milliliterPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Part A: Maximum Observed Plasma Concentration At Steady State (Cmax,ss) Of Pamiparib14572497298525863189
SecondaryPart A: Time To Reach Maximum Plasma Concentration At Steady State (Tmax,ss) Of Pamiparib
Time frame:
Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)
Reported as:
Median · hour
Part A: Time To Reach Maximum Plasma Concentration At Steady State (Tmax,ss) Of Pamiparib
hourPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Part A: Time To Reach Maximum Plasma Concentration At Steady State (Tmax,ss) Of Pamiparib1.0 (0.60 to 6.2)1.1 (0.42 to 4.0)1.0 (1.0 to 7.1)1.9 (0.45 to 7.0)2.0 (0.92 to 3.8)
SecondaryPart A: Ctrough At Steady State (Ctrough,ss) Of Pamiparib
Time frame:
Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)
Reported as:
Geometric mean · nanogram/milliliter
Part A: Ctrough At Steady State (Ctrough,ss) Of Pamiparib
nanogram/milliliterPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Part A: Ctrough At Steady State (Ctrough,ss) Of Pamiparib494 ± 1301170 ± 661151 ± 972135 ± 392554 ± 2.5
SecondaryPart A: ORR

ORR was defined as the percentage of participants with a best overall response of CR and PR.

Time frame:
Starting from Day 1 until disease progression (up to 4 years and 7 months)
Reported as:
Count of participants · Participants
Part A: ORR
ParticipantsPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Part A: ORR13033
SecondaryPart A: PFS

PFS was defined as the time from first dose of study medication to the first documented objective disease progression or death due to any cause, whichever occurred first.

Time frame:
Starting from Day 1 until disease progression (up to 4 years and 7 months)
Reported as:
Median · Days
Part A: PFS
DaysPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Part A: PFS64 (46 to 125)77 (42 to 568)190 (39 to 963)107 (58 to 249)373 (106 to 516)
SecondaryPart A: DCR

DCR was defined as the percentage of participants with a best overall response of CR, PR, and SD.

Time frame:
Starting from Day 1 until disease progression (up to 4 years and 7 months)
Reported as:
Count of participants · Participants
Part A: DCR
ParticipantsPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Part A: DCR36575
SecondaryPart A: CBR

CBR was defined as the percentage of participants with a best overall response of CR, PR, and SD lasting ≥ 24 weeks.

Time frame:
Starting from Day 1 until disease progression (up to 4 years and 7 months)
Reported as:
Median · week
Part A: CBR
weekPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Part A: CBR2 ± 16.75 ± 41.74 ± 66.74 ± 30.84 ± 66.7
SecondaryPart A: OS

OS was defined as the time from the date of first dose of study drug to death due to any cause.

Time frame:
Starting from Day 1 Every 3 months following completion or discontinuation of the treatment (up to 4 years and 7 months)
Reported as:
Median · Days
Part A: OS
DaysPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Part A: OS259 (46 to 437)413 (54 to 1127)NA (107 to NA)434 (128 to 577)NA (178 to NA)
SecondaryPart A: Percentage Of Participants With Anti-drug Antibodies (ADAs) For Tislelizumab

Immunogenicity was summarized by participants who were ADA positive and developed detectable ADAs.

Time frame:
Within 24 hours before the start of the first dose of tislelizumab in Cycle 1, Day 8 of Cycle 1, and Day 1 of Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 9, and Cycle 17
Reported as:
Count of participants · Participants
Part A: Percentage Of Participants With Anti-drug Antibodies (ADAs) For Tislelizumab
ParticipantsPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5
Part A: Percentage Of Participants With Anti-drug Antibodies (ADAs) For Tislelizumab31010
SecondaryPart B: Number Of Participants Experiencing AEs

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. All AEs reported are treatment-emergent, which was defined as having a reported onset time or worsening in severity on or after the date of the first dose of study treatment through 30 days after the last dose (permanent discontinuation of study treatment) or initiation of new anticancer therapy. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Day 1 of Cycle 1 up to 4 years and 7 months
Reported as:
Count of participants · Participants
Part B: Number Of Participants Experiencing AEs
ParticipantsPart B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8
Part B: Number Of Participants Experiencing AEs23231920232021219
SecondaryPart B: Ctrough Of Tislelizumab

As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.

Time frame:
Cycle 4 Day 1 ( 0 hours and 4 hours post dose)
Reported as:
Geometric mean · nanogram/milliliter
Part B: Ctrough Of Tislelizumab
nanogram/milliliterPart B: Dose Expansion Phase
Part B: Ctrough Of Tislelizumab46060 ± 36
SecondaryPart B: Maximum Observed Plasma Concentration (Cmax) Of Tislelizumab

As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.

Time frame:
Cycle 4 Day 1 ( 0 hours and 4 hours) post dose
Reported as:
Geometric mean · nanogram/milliliter
Part B: Maximum Observed Plasma Concentration (Cmax) Of Tislelizumab
nanogram/milliliterPart B: Dose Expansion Phase
Part B: Maximum Observed Plasma Concentration (Cmax) Of Tislelizumab99408 ± 20
SecondaryPart B: Ctrough Of Pamiparib

As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.

Time frame:
Cycle 2 Day 1 (7 hours Post-dose)
Reported as:
Geometric mean · nanogram/milliliter
Part B: Ctrough Of Pamiparib
nanogram/milliliterPart B: Dose Expansion Phase
Part B: Ctrough Of Pamiparib1161 ± 80
SecondaryPart B: Cmax Of Pamiparib

As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.

Time frame:
Cycle 2 (7 hours Post-dose)
Reported as:
Geometric mean · nanogram/milliliter
Part B: Cmax Of Pamiparib
nanogram/milliliterPart B: Dose Expansion Phase
Part B: Cmax Of Pamiparib1850 ± 63
SecondaryPart B: Percentage Of Participants With ADAs For Tislelizumab

Immunogenicity was summarized by participants who developed detectable ADAs. Treatment-emergent ADAs: sum of both treatment-induced ADAs and treatment-boosted ADAs.

Time frame:
24 hours predose of Day 1 of every cycle
Reported as:
Count of participants · Participants
Part B: Percentage Of Participants With ADAs For Tislelizumab
ParticipantsPart B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8
Treatment-emergent ADA001011002
Treatment-boosted ADA000000000
Treatment-induced ADA001011002
Persistent ADA Response000001000
Transient ADA Response001010002
NAb Positive000000000

Adverse events

Collected over Day 1 through 4 years and 7 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Dose Escalation Phase - Cohort 111/12 (91.7%)5/12 (41.7%)12/12 (100%)
Part A: Dose Escalation Phase - Cohort 29/12 (75%)5/12 (41.7%)11/12 (91.7%)
Part A: Dose Escalation Phase - Cohort 32/6 (33.3%)3/6 (50%)5/6 (83.3%)
Part A: Dose Escalation Phase - Cohort 410/13 (76.9%)6/13 (46.2%)12/13 (92.3%)
Part A: Dose Escalation Phase - Cohort 53/6 (50%)5/6 (83.3%)6/6 (100%)
Part B: Dose Expansion Phase - Arm 1a13/23 (56.5%)6/23 (26.1%)21/23 (91.3%)
Part B: Dose Expansion Phase - Arm 1b14/23 (60.9%)16/23 (69.6%)22/23 (95.7%)
Part B: Dose Expansion Phase - Arm 210/19 (52.6%)7/19 (36.8%)16/19 (84.2%)
Part B: Dose Expansion Phase - Arm 39/20 (45%)8/20 (40%)13/20 (65%)
Part B: Dose Expansion Phase - Arm 421/23 (91.3%)14/23 (60.9%)15/23 (65.2%)
Part B: Dose Expansion Phase - Arm 517/20 (85%)10/20 (50%)17/20 (85%)
Part B: Dose Expansion Phase - Arm 615/21 (71.4%)13/21 (61.9%)14/21 (66.7%)
Part B: Dose Expansion Phase - Arm 720/21 (95.2%)8/21 (38.1%)18/21 (85.7%)
Part B: Dose Expansion Phase - Arm 88/10 (80%)8/10 (80%)5/10 (50%)
Most frequent serious events
Showing 10 of 114
Most frequent serious events
EventPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5Part B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8
ConstipationGastrointestinal disorders0/120/120/60/130/60/230/230/190/200/231/200/211/212/10
Small intestinal obstructionGastrointestinal disorders1/120/120/61/130/62/234/230/190/200/231/200/210/211/10
VomitingGastrointestinal disorders0/120/120/62/131/60/231/230/190/200/231/200/210/211/10
PyrexiaGeneral disorders0/121/121/60/131/60/230/231/191/201/230/202/210/210/10
Autoimmune hepatitisHepatobiliary disorders1/120/120/60/131/61/230/230/190/201/230/200/210/210/10
Immune-mediated hepatitisHepatobiliary disorders0/120/120/60/131/62/233/230/190/200/230/201/210/210/10
Malignant biliary obstructionHepatobiliary disorders0/120/121/60/130/60/230/230/190/200/230/200/210/210/10
Escherichia bacteraemiaInfections and infestations0/120/121/60/130/60/230/230/190/200/230/200/210/210/10
Lower respiratory tract infection viralInfections and infestations0/120/121/60/130/60/230/230/190/200/230/200/210/210/10
Pneumocystis jirovecii pneumoniaInfections and infestations0/120/121/60/130/60/230/230/190/200/230/200/210/210/10
Most frequent other events
Showing 10 of 96
Most frequent other events
EventPart A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5Part B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8
NauseaGastrointestinal disorders5/1210/124/610/135/618/2317/2315/198/208/237/2012/2112/213/10
DiarrhoeaGastrointestinal disorders1/126/124/65/133/610/236/238/194/204/236/206/213/211/10
FatigueGeneral disorders7/127/123/67/134/610/2315/2312/1912/205/2311/209/219/215/10
VomitingGastrointestinal disorders1/127/121/65/133/66/235/238/193/202/234/204/213/212/10
AnaemiaBlood and lymphatic system disorders2/122/122/64/133/65/232/2310/195/203/232/205/215/212/10
Back painMusculoskeletal and connective tissue disorders1/123/123/60/133/68/233/235/195/205/234/203/213/210/10
ThrombocytopeniaBlood and lymphatic system disorders0/120/123/60/132/63/231/232/190/200/230/201/210/210/10
Alanine aminotransferase increasedInvestigations1/122/123/63/133/64/233/233/193/202/232/208/211/212/10
Aspartate aminotransferase increasedInvestigations1/122/123/63/131/63/233/233/193/202/232/209/212/212/10
ConstipationGastrointestinal disorders4/123/121/61/131/64/238/235/196/203/238/203/215/210/10

Baseline characteristics

Safety Analysis Set: all participants who received at least 1 dose of tislelizumab and/or pamiparib.

Age, Continuous
Age, Continuous(years)Part A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5Part B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8Total
Mean61.9 ± 9.3958.6 ± 9.5254.5 ± 11.2761.8 ± 11.4264.3 ± 5.9659.5 ± 10.7169.1 ± 8.6850.4 ± 12.4168.0 ± 8.8964.2 ± 9.8758.5 ± 13.7168.9 ± 10.4563.3 ± 9.1160.1 ± 16.2062.3 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5Part B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8Total
Female91151252323190103695140
Male311110002013171512589
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5Part B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8Total
Hispanic or Latino000001121011007
Not Hispanic or Latino1212613622221618211717199210
Unknown or Not Reported0000000112232112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Dose Escalation Phase - Cohort 1Part A: Dose Escalation Phase - Cohort 2Part A: Dose Escalation Phase - Cohort 3Part A: Dose Escalation Phase - Cohort 4Part A: Dose Escalation Phase - Cohort 5Part B: Dose Expansion Phase - Arm 1aPart B: Dose Expansion Phase - Arm 1bPart B: Dose Expansion Phase - Arm 2Part B: Dose Expansion Phase - Arm 3Part B: Dose Expansion Phase - Arm 4Part B: Dose Expansion Phase - Arm 5Part B: Dose Expansion Phase - Arm 6Part B: Dose Expansion Phase - Arm 7Part B: Dose Expansion Phase - Arm 8Total
American Indian or Alaska Native000000000000000
Asian2012020002100212
Native Hawaiian or Other Pacific Islander000001001100003
Black or African American000000000010203
White1012511620231718181618198201
More than one race000000000000000
Unknown or Not Reported0000000212230010
08

Study locations

29 sites
  • Pinnacle Oncology Hematology
    Scottsdale, Arizona 85258, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Texas Oncology
    Dallas, Texas 75246, United States
  • Texas Oncology
    Tyler, Texas 75702, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • The Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Mid North Coast Cancer Institute
    Coffs Harbour, New South Wales 2450, Australia
  • Calvary Mater Newcastle
    Newcastle, New South Wales 2298, Australia
  • Westmead Hospital
    Parramatta, New South Wales, Australia
  • Prince of Wales
    Randwick, New South Wales, Australia
  • Northern Cancer Institute
    St Leonards, New South Wales 2065, Australia
  • Icon Cancer Care
    Brisbane, Queensland 4101, Australia
  • Monash Health
    Clayton, Victoria, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria, Australia
  • Linear Clinical Research Ltd
    Nedlands, Western Australia, Australia
  • Institut Gustave Roussy
    Paris, 94800, France
  • Centre Eugene Marquis
    Rennes, 35042, France
  • Auckland City Hospital
    Auckland, 1023, New Zealand
  • Capital and Coast District Health Board
    Wellington, 6021, New Zealand
  • Hospital Universitario Vall d'Hebrón
    Barcelona, 08035, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • Sarah Cannon Research Institute
    London, W1G 6AD, United Kingdom
09

References and documents

Publications

  • Friedlander M, Meniawy T, Markman B, Mileshkin L, Harnett P, Millward M, Lundy J, Freimund A, Norris C, Mu S, Wu J, Paton V, Gao B. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019 Sep;20(9):1306-1315. doi: 10.1016/S1470-2045(19)30396-1. Epub 2019 Aug 1. PubMed 31378459 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Sep 2020, 55 months.

Results were first posted in Dec 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2016
First posted
Jan 21, 2016
StartActual
Feb 2, 2016
Primary completionActual
Sep 9, 2020
CompletionActual
Sep 9, 2020
Results first posted
Dec 6, 2021
Last update
Dec 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02660034
Lead sponsor
BeiGene
Collaborators
Myriad Genetic Laboratories, Inc.
Responsible party
Sponsor
First posted
Jan 21, 2016
Start date
Feb 2, 2016
Primary completion
Sep 9, 2020
Completion
Sep 9, 2020
Results posted
Dec 6, 2021
Last update
Dec 6, 2021

Study contacts

Study Director
principal investigator · BeiGene
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Pamiparib

Start the discussion